Viking Therapeutics' stock surged 12.26% in pre-market trading, as investor optimism was fueled by several encouraging updates regarding the company's clinical development pipeline for obesity treatments.

The biopharmaceutical company announced plans to advance its oral VK2735 formulation into Phase 3 trials for obesity in the third quarter of 2026. This move is seen as a key differentiator, as VK2735 could become the only dual GLP-1/GIP agonist available in both oral and injectable forms. Additional positive updates included strong enrollment progress in the ongoing Phase 3 VANQUISH trials for the subcutaneous formulation, the completion of enrollment for a VK2735 maintenance dosing study with data expected in 3Q26, and plans to file an Investigational New Drug (IND) application for a novel amylin agonist this quarter.

These developments overshadowed the company's fourth-quarter financial results, which showed a wider-than-expected net loss primarily due to increased research and development spending. Investors appeared to focus on the long-term potential of Viking's obesity portfolio and the company's strong year-end cash position of $706 million, which provides ample resources to advance its clinical programs.